3 OVERALL PROGRAM CRITIQUE 3 PROGRESS DURING THE CURRENT FUNDING PERIOD 3 PROGRAM LEADERSHIP 4 PROGRAM AS AN INTEGRATED EFFORT 5 PROJECT AND CORE SUMMARIES OF DISCUSSION 6 COLLABORATING INSTITUTIONS 9 ADDITIONAL REVIEW CRITERIA (Resume) 10 PROTECTION OF HUMAN SUBJECTS (Resume) 10 VERTEBRATE ANIMALS (Resume) 10 ADDITIONAL REVIEW CONSIDERATIONS (Resume) 10 INDIVIDUAL PROJECTS AND CORES 11 PROJECT 1: Mechanisms of Transformation by TAL1/SCL in Thymic Malignancy 11 PROJECT 2: Molecular Pathways in T-cell Development and T-ALL 19 PROJECT 3: The Molecular Function of D-cyclins in T-ALL 27 PROJECT 4: Role of DNA Double Strand Break Response in Suppression of Thymic Lymphoma 32 CORE A: Administrative Core 47 CORE B: Biostatistics and Bioinformatics Core 49 COMMITTEE BUDGET RECOMMENDATIONS 52 SPECIAL EMPHASIS PANEL ROSTER DESCRIPTION (provided by applicant): This proposal is based on the central hypothesis that improved understanding of the molecular pathways that contributing to the disordered regulation of cell proliferation, differentiation, and apoptosis in T-cell lymphoblastic leukemia and lymphoma (T-ALL/T-LBL) will ultimately lead to improved therapy of these diseases. The research will be accomplished through the coordinated efforts of 5 research projects and 2 cores. In Project 1, Tom Look will work closely with Rick Young to identify downstream target genes within TAL1-mediated transcriptional networks that contribute to the disordered regulation of cell proliferation, differentiation, and apoptosis in human T-cell malignancies. In Project 2, Harald von Boehmer will identify molecular pathways that cooperate with Notch1 signaling in lymphomagenesis by analyzing the impact of insertional mutagenesis, epigenetic regulation, and miRNA-dependent regulation on the generation of T-ALL from in Notch1 overexpressing T-cell progenitors. In Project 3, Peter Sicinski will study the molecular function of D-cyclins in Notch-driven murine T-ALL model (together with Harald von Boehmer) and in human T-ALL (with Tom Look). In Project 4, Fred Alt will elucidate molecular mechanisms and activated pathways associated with recurrent chromosomal translocations in thymic leukemias and lymphomas. In Project 5, Rick Young will identify the epigenetic mechanisms regulating normal T cell development and leukemogenesis and link them to the oncogenic action of TAL1 and Notch1 in T-ALL. Discoveries in murine models made by Drs. von Boehmer, Sicinski, Alt and Young will be immediately translated to determine relevance to human T-ALL/LBL molecular pathogenesis in collaboration with Dr. Look. These projects will be augmented with a Biostatistics Core (Donna Neuberg), to assist with the analysis of microarray data and the optimal design of animal experiments;and an Administrative Core (Tom Look and Harald von Boehmer), to oversee the administration and coordination of the research interactions among program investigators. Such interactions are expected to accelerate the pace at which important discoveries are generated in these projects and in the program as a whole.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA109901-06
Application #
7765900
Study Section
Special Emphasis Panel (ZCA1-RPRB-O (O1))
Program Officer
Mufson, R Allan
Project Start
2004-08-11
Project End
2015-03-31
Budget Start
2010-04-15
Budget End
2011-03-31
Support Year
6
Fiscal Year
2010
Total Cost
$1,988,819
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Lobbardi, Riadh; Pinder, Jordan; Martinez-Pastor, Barbara et al. (2017) TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discov 7:1336-1353
Rahman, Sunniyat; Magnussen, Michael; León, Theresa E et al. (2017) Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. Blood 129:3221-3226
Winter, Georg E; Mayer, Andreas; Buckley, Dennis L et al. (2017) BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. Mol Cell 67:5-18.e19
Li, Z; Abraham, B J; Berezovskaya, A et al. (2017) APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL. Leukemia 31:2057-2064
Abraham, Brian J; Hnisz, Denes; Weintraub, Abraham S et al. (2017) Small genomic insertions form enhancers that misregulate oncogenes. Nat Commun 8:14385
Erb, Michael A; Scott, Thomas G; Li, Bin E et al. (2017) Transcription control by the ENL YEATS domain in acute leukaemia. Nature 543:270-274
Zhang, Tinghu; Kwiatkowski, Nicholas; Olson, Calla M et al. (2016) Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol 12:876-84
Hnisz, Denes; Weintraub, Abraham S; Day, Daniel S et al. (2016) Activation of proto-oncogenes by disruption of chromosome neighborhoods. Science 351:1454-1458
Akahane, K; Sanda, T; Mansour, M R et al. (2016) HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia 30:219-28
Tan, S H; Yam, A W Y; Lawton, L N et al. (2016) TRIB2 reinforces the oncogenic transcriptional program controlled by the TAL1 complex in T-cell acute lymphoblastic leukemia. Leukemia 30:959-62

Showing the most recent 10 out of 62 publications